- Tytuł:
- Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF
- Autorzy:
- Źródło:
- The Patient - Patient-Centered Outcomes Research. October 2015 8(5):445-454
Czasopismo naukowe